(Updates with the stock move in the headline and the first paragraph.)
Soleno Therapeutics (SLNO) shares jumped 37% in premarket activity Thursday after the company said overnight that the US Food and Drug Administration approved its treatment for hyperphagia in adults and children with Prader-Willi Syndrome, a rare genetic disorder.
The approval for the company's VYKAT XR tablets was based on efficacy and safety data from a phase 3 trial, it said late Wednesday.
Soleno expects the tablets to be available in the US in April.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。